More about Jubilant Ingrevia Limited
Fundamentals for Jubilant Ingrevia Limited
Regulatory Filings for Jubilant Ingrevia Limited
IndiGo Implements Steep Fuel Surcharge as Iran Conflict Sends Jet Fuel Costs Soaring
The RBI's New Forex Fortress: Defensive Maneuvers in an Era of Oil Shocks
India's Fiscal Milestone: GST Collections Breach ₹2 Lakh Crore Mark for the First Time
AI Disruption Accelerates: Oracle Layoffs Raise Alarms for India’s Tech Workforce
Fundamentals for Jubilant Ingrevia Limited
Business Operations:
Sector: Basic MaterialsIndustry: Specialty Chemicals
Jubilant Ingrevia Limited engages in the life science products and solutions in India, the United States, Europe, China and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Chemical Intermediates. The Specialty Chemicals segment offers bio-pyridine and -picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions. The Nutrition & Health Solutions segment provides nutrition and health ingredients; and animal and human nutrition health solutions. The Chemical intermediates segment offers acetyls and specialty ethanol. The company provides piperidines, metal complexes, choline salts, vitamin B3, Vitamin B4, picolinates, riboflavin phosphate sodium, nutritional premixes, antioxidants, straight ingredients, acetic anhydride, acetic acid, ethyl acetate, propionic anhydride, formaldehyde, bio acetic acid-food grade, acetaldehyde, and ethanol, as well as cyano, acetyl, amino, halo, alkyl, and aldehyde pyridines. In addition, it offers route design, process development, process optimization, and scale-up and commercial manufacturing of intermediates. Further, the company provides vitamins, mineral premixes, stress regulator, amino acid, herbal choline, herbal non-antibiotic growth promoter and egg quality enhancer, toxin binder, acidifiers, and enzymes and emulsifiers. It serves pharmaceutical, animal and human nutrition, agrochemical, personal and consumer care, and industrial customers. The company was formerly known as Jubilant LSI Limited and changed its name to Jubilant Ingrevia Limited in October 2020. Jubilant Ingrevia Limited was incorporated in 2019 and is headquartered in Noida, India.
Revenue projections:
Revenues for Jubilant Ingrevia Limited are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.
Financial Ratios:
| currentRatio | 0.00000 |
|---|---|
| forwardPE | 25.71298 |
| debtToEquity | 26.51000 |
| earningsGrowth | -0.32300 |
| revenueGrowth | -0.00500 |
| grossMargins | 0.47382 |
| operatingMargins | 0.07756 |
| trailingEps | 16.75000 |
| forwardEps | 23.42591 |
With JUBLINGREA's Forward PE in a favorable range, the stock appears reasonably priced compared to its earnings. This suggests that it's not overpriced and there is room for growth, providing an encouraging opportunity for investors seeking future value increases.
JUBLINGREA's low Debt-to-Equity ratio indicates the company is not over-leveraged. This suggests a balanced financial structure with limited reliance on debt, which reduces financial risk and enhances its stability, making JUBLINGREA's financial position more secure and appealing to investors.
Jubilant Ingrevia Limited's low earnings and revenue growth suggest that the company may face shrinking profits. This could indicate underlying financial challenges, making it difficult for Jubilant Ingrevia Limited to sustain its current profitability.
Jubilant Ingrevia Limited's negative gross and operating margins indicate that the company is currently unprofitable at both the production and operational levels. This suggests significant challenges in managing costs and generating revenue, which could impact its overall financial health.
JUBLINGREA's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that JUBLINGREA is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.
Price projections:
Jubilant Ingrevia Limited's price has consistently remained near the lower edge of projections, suggesting that it is not fully meeting market expectations. This could indicate a need for improved performance or strategies to boost investor confidence.
Insider Transactions:
2 JUBLINGREA transactions were recorded, when the market price was 686.4500122070312.JUBLINGREA stock was bought in 9 transactions, while the market price was at 721.272230360243.The insider transaction data shows no clear pattern or trend, making it difficult to draw any meaningful conclusions about the company's current direction based on this information.
Recommendation changes over time:
The recent buy bias for Jubilant Ingrevia Limited from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see Jubilant Ingrevia Limited as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
U.S. Labor Market in 2026: JOLTS and Consumer Confidence Reveal Why Hiring Cooled Without Unemployment Spike
Lending Unleashed: Assessing the Impact of the Federal Reserve’s Capital Rollback
Calendar Collision: How Mahavir Jayanti's Overlap With Fiscal Year-End Reshapes India's Tax-Loss Harvesting Landscape